Analyst stock forecast
Xeris Biopharma Holdings Forecast: $11.71 Analyst Target
XERS has a $11.71 target, Strong Buy rating and 7 analysts. As of 2026-08-22.
Direct answer
Xeris Biopharma Holdings's average price target is $11.71.
The target implies +34.6% from the recorded current price, and the consensus rating is Strong Buy.
The low target implies -8%, the high target implies +106.9%, and the range spans 114.9% of the current price.
Forecast evidence checked August 22, 2026.
Get free Xeris Biopharma Holdings email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $8.70
- Average price target
- $11.71
- High price target
- $18.00
- Low price target
- $8.00
- Low target gap
- -8%
- Target upside
- +34.6%
- High target gap
- +106.9%
- Target range width
- 114.9%
- Consensus rating
- Strong Buy
- Analysts
- 7
- Evidence date
- August 22, 2026
- Valid through
- August 29, 2026
Explore related company data
Read the frequently asked questions.
What is Xeris Biopharma Holdings's average price target?
Xeris Biopharma Holdings's verified average price target is $11.71. The target range is $8.00 to $18.00.
How far are Xeris Biopharma Holdings's low and high targets from the recorded price?
The low target implies -8%, while the high target implies +106.9%.
How many analysts are included in Xeris Biopharma Holdings's consensus?
The verified consensus includes 7 analysts.
How is Xeris Biopharma Holdings's target upside or downside calculated?
The average target of $11.71 is divided by the recorded price of $8.70, then one is subtracted to produce +34.6%. This does not guarantee a future return.
When was Xeris Biopharma Holdings's analyst forecast verified?
The data was verified on 2026-08-22. The dataset is valid through 2026-08-29.